KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to -$117.0 million.

  • Vertex Pharmaceuticals' Cash from Investing Activities rose 6637.93% to -$117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year increase of 6142.49%. This contributed to the annual value of -$3.8 billion for FY2024, which is 1999.87% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Cash from Investing Activities of -$117.0 million as of Q3 2025, which was up 6637.93% from -$484.5 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Cash from Investing Activities registered a high of $175.6 million during Q4 2022, and its lowest value of -$2.1 billion during Q1 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' median Cash from Investing Activities value was -$134.0 million (recorded in 2021), while the average stood at -$433.2 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Cash from Investing Activities surged by 23104.48% in 2022 and then tumbled by 349529.41% in 2023.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Cash from Investing Activities stood at -$134.0 million in 2021, then skyrocketed by 231.04% to $175.6 million in 2022, then tumbled by 604.84% to -$886.5 million in 2023, then increased by 7.29% to -$821.9 million in 2024, then soared by 85.76% to -$117.0 million in 2025.
  • Its Cash from Investing Activities stands at -$117.0 million for Q3 2025, versus -$484.5 million for Q2 2025 and -$55.8 million for Q1 2025.